These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23496666)

  • 41. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
    Xing P; Wang H; Yang S; Han X; Sun Y; Shi Y
    BMC Immunol; 2018 Apr; 19(1):14. PubMed ID: 29661145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
    McCarthy F; Roshani R; Steele J; Hagemann T
    J Leukoc Biol; 2013 Dec; 94(6):1201-6. PubMed ID: 23695306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
    Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
    Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine immunotherapy in lung cancer: Clinical experience and future directions.
    Freeman-Keller M; Goldman J; Gray J
    Pharmacol Ther; 2015 Sep; 153():1-9. PubMed ID: 25989231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of targeted therapy in non-small cell lung cancer.
    Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
    Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.
    Hernández AM; Rodríguez N; González JE; Reyes E; Rondón T; Griñán T; Macías A; Alfonso S; Vázquez AM; Pérez R
    J Immunol; 2011 Mar; 186(6):3735-44. PubMed ID: 21300821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Vaccines for the treatment of non-small cell lung cancer].
    Leduc C; Quoix E
    Rev Mal Respir; 2019 Mar; 36(3):415-425. PubMed ID: 30902445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?
    Viaud S; Théry C; Ploix S; Tursz T; Lapierre V; Lantz O; Zitvogel L; Chaput N
    Cancer Res; 2010 Feb; 70(4):1281-5. PubMed ID: 20145139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Non-small cell lung cancer: news from immunotherapy].
    Reinmuth N; Heigener DF; Reck M
    Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
    Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
    Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Latest therapeutic strategy for stage IV non-small cell lung cancer].
    Kawate N
    Nihon Rinsho; 2002 May; 60 Suppl 5():490-3. PubMed ID: 12101720
    [No Abstract]   [Full Text] [Related]  

  • 57. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials.
    Choudhury A; Palma M; Mellstedt H
    Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S37-44. PubMed ID: 18540533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-small-cell lung cancer: multimodality approach in stage-III resectable disease.
    Thomas M; Hoffknecht P; Droege C; Baisch A; Reinmuth N; Kreuter M; Lange T; Berdel WE
    Lung Cancer; 2004 Aug; 45 Suppl 2():S99-105. PubMed ID: 15552789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of new targeted therapies in small-cell lung cancer.
    Rossi A; Maione P; Colantuoni G; Guerriero C; Gridelli C
    Crit Rev Oncol Hematol; 2004 Jul; 51(1):45-53. PubMed ID: 15207253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
    Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.